Clinical Trials Sponsored by AstraZeneca Turkey

Total 5398 results

AstraZeneca

Recruiting

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma (TREMENDOUS)

Hepatocellular Carcinoma

China
AstraZeneca

Recruiting

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Asthma

United States
AstraZeneca

Recruiting

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (ZEAL)

Liver Cirrhosis

Denmark, Spain, Germany, United States, France, Australia, China, Netherlands, Belgium, Switzerland, Austria, United Kingdom, Taiwan, Canada, Czechia
AstraZeneca

Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NIS durvalumab)

NSCLC, Non-small-cell Lung Carcinoma

Russian Federation
AstraZeneca

Recruiting

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

Life Threatening Bleeding | Factor Xa Inhibitor

Japan
AstraZeneca

Recruiting

PASS of Paediatric Patients Initiating Selumetinib

Neurofibromatosis Type 1

Spain, United Kingdom, Israel, France, Italy, Portugal, Switzerland, Germany, Austria
AstraZeneca

Recruiting

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)

Prostate Cancer

United States, China, Israel, Korea, Republic of, Canada, Poland, Spain, Belgium, Hungary, Japan, United Kingdom, France, Brazil, Taiwan, Australia, Turkey, Chile, Czechia, India, Mexico, Netherlands, Greece
AstraZeneca

Recruiting

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)

Chronic Kidney Disease | Hyperkalaemia

Spain, United Kingdom, Belgium, Italy, Netherlands, France, Germany
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, Germany, United Kingdom, China, Philippines, Italy, Chile, Taiwan, Thailand, France, Puerto Rico, Israel, Peru, Colombia, Poland, Brazil, Russian Federation, Romania, Greece
AstraZeneca

Recruiting

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)

Lupus Nephritis

China, United States, Hungary, Germany, Italy, Belgium, India, Mexico, Vietnam, Argentina, Bulgaria, Colombia, Japan, Turkey, Taiwan, Thailand, France, Netherlands, Brazil, Malaysia, Peru, Poland, Russian Federation
AstraZeneca

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Australia, Spain, United Kingdom, Korea, Republic of, Canada, Italy, Poland, Belgium, China, Japan, Taiwan, Thailand, Hungary, Netherlands
AstraZeneca

Recruiting

FASENRA Regulatory Postmarketing Surveillance in Korea

Asthma

Korea, Republic of
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
AstraZeneca

Recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction Cancer

United States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia
AstraZeneca

Recruiting

D9319C00001- 1L OC Mono Global RCT (MONO-OLA1)

Ovarian Cancer

China, Vietnam, Russian Federation, Ukraine, South Africa, Turkey, India, Peru, Colombia, Poland, Chile, Philippines
AstraZeneca

Recruiting

ALICIA (Acalabrutinib in CLL Therapy) (ALICIA)

Chronic Lymphocytic Leukemia

Russian Federation
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Taiwan, Australia
AstraZeneca

Recruiting

Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

Ovarian Cancer | Prostate Cancer

China
AstraZeneca

Recruiting

'OLAP' (OLAparib Regulatory Post-marketing Surveillance) (OLAP)

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer

Korea, Republic of
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
AstraZeneca

Recruiting

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics (CHINOOK)

Asthma

Canada, Denmark, United States, Sweden, United Kingdom
AstraZeneca

Active, not recruiting

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Carcinoma, Non-Small-Cell Lung

Japan
AstraZeneca

Active, not recruiting

Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients (iOUTRUN)

Severe Asthma

United Arab Emirates, Brazil, Qatar, Saudi Arabia, Colombia, Dominican Republic, India, Kuwait
AstraZeneca

Completed

Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines (ATTEST)

Covid-19

United Kingdom
AstraZeneca

Active, not recruiting

A Study of CIN-107 in Adults With Primary Aldosteronism

Primary Aldosteronism | Hyperaldosteronism

United States
AstraZeneca

Active, not recruiting

Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries (EVOLVE)

COVID-19

United Arab Emirates
AstraZeneca

Active, not recruiting

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Healthy Participants

Germany
AstraZeneca

Active, not recruiting

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

Carcinoma, Non-Small-Cell Lung

Poland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer | Hematological Malignancies | Solid Tumor Pediatric

Spain, Italy, United States, United Kingdom, France, Netherlands, Germany
AstraZeneca

Active, not recruiting

Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece (EVOLUTION-HF)

Heart Failure

Greece
AstraZeneca

Active, not recruiting

HF Prevalence and Evolution of HF in DM II Patients at High Risk (HF-LanDMark)

RELATED REGISTRY SEARCH

Greece
AstraZeneca

Active, not recruiting

Forxiga HF General Drug Use-Results Study

Heart Failure

Japan
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

Advanced or Metastatic NSCLC

Russian Federation
AstraZeneca

Completed

Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)

Breast Cancer, HER2

China
AstraZeneca

Active, not recruiting

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (L-MOCA)

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive

China, Malaysia
AstraZeneca

Active, not recruiting

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

Biliary Tract Neoplasms

France, Italy, United States, Thailand, Korea, Republic of, United Kingdom, India, Japan, Poland, Russian Federation, Turkey, China, Taiwan, Hong Kong, Chile, Bulgaria, Argentina
AstraZeneca

Active, not recruiting

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging (BURAN)

Asthma

United States, Belgium, United Kingdom, France, Portugal, Australia, Spain
AstraZeneca

Completed

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)

SARS-CoV-2

United States, Belgium, United Kingdom, Brazil, Germany
AstraZeneca

Active, not recruiting

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)

Carcinoma, Non-Small-Cell Lung | Small Cell Lung Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States, Taiwan, Korea, Republic of, Japan, Spain
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
AstraZeneca

Terminated

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Steatohepatitis

United States, Puerto Rico
AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
AstraZeneca

Active, not recruiting

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

Hepatocellular Carcinoma

United States, Canada, Brazil, France, Italy, Russian Federation, Spain, Vietnam, Korea, Republic of, China, Germany, Ukraine, Japan, Hong Kong, Taiwan, India, Thailand
AstraZeneca

Active, not recruiting

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)

Hormone-Sensitive Prostate Cancer

United States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
AstraZeneca

Active, not recruiting

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA)

Eosinophilic Granulomatous Vasculitis

United States, Canada, France, Italy, Israel, United Kingdom, Japan, Germany, Belgium

Clinical Trials Sponsored by AstraZeneca Turkey

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations